GlassScriptPhysician profile
Gary W Mcewen
NPI 1477554657
$6,582.67
in general payments reported to CMS, 2019-2025
31 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $67.65 · 2021: $359 · 2022: $1,674 · 2023: $1,475 · 2024: $1,538 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,073.51 |
| Education | $243.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,210.03 | 2021-2025 | |
| Janssen Biotech, INC. | $631.43 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $611.62 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $508.26 | 2021-2025 | Sotyktu |
| Ucb, INC. | $427.80 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $392.24 | 2020-2025 | Dupixent, Libtayo |
| Amgen INC. | $352.99 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $315.01 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $309.59 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $297.90 | 2022-2025 | |
| Almirall LLC | $254.03 | 2021-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $188.63 | 2023-2025 | Zoryve |
| Organogenesis INC. | $187.51 | 2024-2025 | Affinity |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.09 | 2021-2025 | Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $134.51 | 2022-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $123.54 | 2022-2025 | |
| Leo Pharma INC. | $90.42 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $61.22 | 2022-2025 | Aklief, Epsolay, Twyneo |
| Aclaris Therapeutics, INC. | $57.56 | 2019 | |
| Kyowa Kirin, INC. | $36.78 | 2023-2024 | Poteligeo |
| Celgene Corporation | $36.45 | 2019 | |
| Journey Medical Corporation | $33.34 | 2022 | |
| Genentech USA, INC. | $27.70 | 2023-2024 | Erivedge |
| Prugen, INC. Pharmaceuticals | $22.43 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $21.73 | 2019 | |
| Organon LLC | $17.56 | 2025 | Renflexis, Hadlima |
| Sandoz INC. | $16.84 | 2023 | Hyrimoz |
| Epi Health, LLC | $14.26 | 2021 | |
| Vyne Pharmaceuticals INC. | $13.71 | 2020 | |
| Pfizer INC. | $13.39 | 2021 | |
| Mayne Pharma Commercial LLC | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Mcewen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.